Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension.

Who Took Part

The study group was 1961 adults.

PubMed indexes the participants as adults.

At week 68, treatments (including lifestyle intervention) were discontinued.

An off-treatment extension assessed for a further year a representative subset of participants who had completed 68 weeks of treatment.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Some adults received a placebo instead of Semaglutide, giving a reference point.

This subset comprised all eligible participants from any site in Canada, Germany and the UK, and sites in the United States and Japan with the highest main phase recruitment.

All analyses in the extension were exploratory.

What Was Measured

PubMed files the paper under topics including Cardiovascular Diseases, Diabetes Mellitus, Glucagon-Like Peptides, Weight Gain and Semaglutide.

Author keywords: GLP-1 analogue, antiobesity drug, clinical trial, obesity therapy, phase III study and weight control.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Semaglutide in 1961 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.